BDR Pharma launches generic Midostaurin for treatment of Leukemia

INDIA – BDR Pharma, one of India’s leading generic pharmaceutical companies, has launched the country’s first generic-midostaurin under the brand name MSTARIN, which is indicated in rare, difficult-to-treat cancers.

The drug is approved for use in combination with standard Daunorubicin and Cytarabine induction and high-dose Cytarabine consolidation chemotherapy, as well as for patients with newly diagnosed FLT3-positive Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia is the most common type of adult leukemia or blood cancer. It accounts for approximately 25% of all adult leukemias worldwide, and has the highest incidence rates as well as the lowest survival rates of any adult leukemia.

”With the launch of the generic Midostaurin, patients with FLT3 mutated AML will now have access to this medicine at an affordable cost that could significantly extend their lives,” BDR Pharmaceuticals Director – Business Development Raheel Shah stated.

Throughout 2020-2021, the Mumbai-based pharmaceutical company made headlines for being a frontrunner in the race to develop drugs to combat the Coronavirus.

When the country desperately needed a self-sufficient supply of virus-fighting drugs, the home-based company played a significant role in manufacturing Covid 19 drugs and making a whole basket of such drugs available to Indian patients.

BDR is known as a “niche” player in the production of pharmaceutical Active Pharmaceutical Ingredients (APIs) and renowned new age formulations.

Over the last 15 years, the BDR Group of companies has steadily expanded in the pharmaceutical industry, both domestically and internationally.

The group is primarily supported by its two companies, BDR Pharmaceuticals International Pvt Ltd and BDR Life Sciences Pvt. Ltd, each of which has established its own dominance in its respective fields, namely API and formulation manufacturing, respectively.

BDR Pharma focuses on development in specialized therapeutic areas such as oncology, critical care, gynecology, neurology, dermatology, and women’s health.

In September, BDR Pharmaceuticals announced that it has launched generic Cabozantinib, which is used to treat various types of cancer.

Cabozantinib is used to treat metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma, according to BDR Pharma.

The medication is available in dosages of 20 mg, 40 mg, and 60 mg, according to the company.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.